Cu-CPT22 is primarily utilized in the field of cancer research due to its potential as an anticancer agent. It is studied for its ability to induce apoptosis in cancer cells, making it a promising candidate for chemotherapy. The compound is also explored for its role in enhancing the efficacy of other anticancer drugs when used in combination therapies. Researchers are investigating its mechanism of action to better understand how it targets and disrupts cancer cell proliferation. Additionally, Cu-CPT22 is being examined for its potential to overcome drug resistance in certain types of cancer, offering new avenues for treatment. Its application extends to preclinical studies, where it is tested for safety, toxicity, and therapeutic effectiveness in various cancer models.